OncologyImmunotherapy alone beat chemo for a common type of womb cancer
In the KEYNOTE-C93 trial, pembrolizumab without chemotherapy kept dMMR endometrial cancer in check for a median 38.2 months, against 8.4 months with chemotherapy, with fewer severe side effects.
26 October 2026